RNA Gets a $2.4B Promotion at Eli Lilly

Eli Lilly acquires Orna Therapeutics for up to $2.4B, bringing circular RNA and in vivo CAR-T into its US pipeline

6 Apr 2026

Eli Lilly has never been shy about spending. But its February agreement to acquire Orna Therapeutics, a small firm in Watertown, Massachusetts, for up to $2.4bn is notable less for its size than for what it signals about where the pharmaceutical industry believes medicine is heading.

Orna's core asset is circular RNA, a looped variant of the molecule that conventional mRNA therapies rely on. The looped structure makes it more durable and more effective at producing proteins than its linear counterpart. Combined with lipid nanoparticles engineered to travel beyond the liver, the platform is designed to deliver genetic instructions directly to immune cells inside a living patient, skipping the laboratory manufacturing steps that make conventional cell therapies so expensive and logistically cumbersome.

The lead programme, ORN-252, targets CD19, a protein found on the surface of the B cells implicated in autoimmune conditions such as rheumatoid arthritis and multiple sclerosis. Data presented at a haematology conference in December 2025 showed meaningful immune cell depletion in animal models, and, crucially, without the toxic preconditioning regimens that currently limit CAR-T therapies to patients healthy enough to withstand them. Lilly considers ORN-252 ready for human trials.

The deal fits a pattern of large-scale consolidation in the sector. Bristol Myers Squibb paid $1.5bn for Orbital Therapeutics in October 2025; AbbVie committed $2.1bn to Capstan Therapeutics the previous June. Lilly's willingness to top both suggests that in vivo cell engineering has crossed a threshold: no longer a speculative wager, but a strategic necessity for any firm serious about the future of immunology and oncology.

The acquisition is structured with an upfront sum and further payments contingent on clinical milestones, tying Orna's founders and Lilly's shareholders to the same set of outcomes. That alignment may prove important. Circular RNA has moved fast from laboratory curiosity to boardroom priority, but the distance between promising preclinical data and a licensed medicine remains vast, and strewn with the wreckage of earlier biological platforms that looked equally compelling at a similar stage.

Whether the loop, in the end, closes, remains the question worth watching.